微泡
血脑屏障
药物输送
脑瘤
胶质母细胞瘤
医学
胶质瘤
脑癌
药物输送到大脑
外体
药品
癌症
神经科学
癌症研究
生物信息学
病理
小RNA
药理学
生物
中枢神经系统
内科学
纳米技术
基因
材料科学
生物化学
作者
Seyyed Hossein Khatami,Neda Karami,Mortaza Taheri‐Anganeh,Sina Taghvimi,G.H. Tondro,Marjan Khorsand,Elahe Soltani Fard,Najmeh Sedighimehr,Marzieh Kazemi,Khojaste Rahimi Jaberi,Mostafa Moradi,Parvaneh Nafisi Fard,Mohammad Hasan Darvishi,Ahmad Movahedpour
标识
DOI:10.1007/s12035-023-03365-0
摘要
Gliomas make up virtually 80% of all lethal primary brain tumors and are categorized based on their cell of origin. Glioblastoma is an astrocytic tumor that has an inferior prognosis despite the ongoing advances in treatment modalities. One of the main reasons for this shortcoming is the presence of the blood-brain barrier and blood-brain tumor barrier. Novel invasive and non-invasive drug delivery strategies for glioblastoma have been developed to overcome both the intact blood-brain barrier and leverage the disrupted nature of the blood-brain tumor barrier to target cancer cells after resection-the first treatment stage of glioblastoma. Exosomes are among non-invasive drug delivery methods and have emerged as a natural drug delivery vehicle with high biological barrier penetrability. There are various exosome isolation methods from different origins, and the intended use of the exosomes and starting materials defines the choice of isolation technique. In the present review, we have given an overview of the structure of the blood-brain barrier and its disruption in glioblastoma. This review provided a comprehensive insight into novel passive and active drug delivery techniques to overcome the blood-brain barrier, emphasizing exosomes as an excellent emerging drug, gene, and effective molecule delivery vehicle used in glioblastoma therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI